959 / 1851
Vansteenkiste J, et al. Ann Oncol. 2013;24
PORT may be considered for fit patients with completely resected NSCLC with
N2
nodal involvement
, preferably after completion of adjuvant chemotherapy. This
may
reduce local recurrences
(
25-30% gain
), although no survival benefit has
been demonstrated [III, B]
A
randomised clinical trial to assess the effect on survival is ongoing
(LUNGART, NCT00410683)
PORT
can be indicated in case of a R1 or R2 resection
, although survival in
these patients remains poor [III, B]